Published in Ann Chir on June 01, 2001
Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg (2006) 2.49
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer (2011) 1.15
Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates. Radiology (2009) 1.08
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery (2012) 0.94
Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol (2010) 0.92
Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J (2014) 0.90
Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina. HPB (Oxford) (2007) 0.86
Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg (2013) 0.82
Surgery for liver metastases from breast cancer. HPB (Oxford) (2006) 0.81
A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB (Oxford) (2013) 0.79
Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet (1992) 5.49
Age as prognostic factor in premenopausal breast carcinoma. Lancet (1993) 4.31
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer (1996) 2.95
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Association of p53 mutations with short survival in colorectal cancer. Gastroenterology (1994) 2.19
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
Recurrence in the axilla after sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol (2002) 2.03
Survival and acquired genetic alterations in colorectal cancer. Gastroenterology (1992) 2.02
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer (1996) 1.97
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Multiple genetic alterations in distal and proximal colorectal cancer. Lancet (1989) 1.87
Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol (2001) 1.84
Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol (2000) 1.71
Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.68
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer (1994) 1.60
Multi-state Markov models in cancer screening evaluation: a brief review and case study. Stat Methods Med Res (2010) 1.60
Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer (1996) 1.55
Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective study. Int J Radiat Oncol Biol Phys (1995) 1.52
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer (1998) 1.52
Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology (2006) 1.47
Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest (1996) 1.42
A multivariate primary tumour control analysis in 465 patients treated by radical radiotherapy for cancer of the tonsillar region: clinical and treatment parameters as prognostic factors. Radiother Oncol (1989) 1.40
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst (1989) 1.40
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39
A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer (1995) 1.38
Breast cancer in elderly women: a retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation. Int J Radiat Oncol Biol Phys (1995) 1.38
Modelling the effect of breast cancer screening on related mortality using French data. Cancer Epidemiol (2010) 1.37
Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol (1995) 1.32
Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res (1998) 1.32
M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem (1992) 1.31
Targeting HER2 in other tumor types. Ann Oncol (2001) 1.29
Prospective evaluation of late cosmetic results following breast reconstruction: I. Implant reconstruction. Plast Reconstr Surg (2001) 1.27
A regression survival model for testing the proportional hazards hypothesis. Biometrics (1996) 1.27
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res (2000) 1.24
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
Attempts at immunotherapy of 100 patients with acute lymphoid leukemia: some factors influencing results. Natl Cancer Inst Monogr (1972) 1.20
Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect (2003) 1.19
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer (2001) 1.17
Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer (1988) 1.17
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer (1996) 1.16
Oncoplastic breast surgery: a review and systematic approach. J Plast Reconstr Aesthet Surg (2009) 1.16
Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res (2006) 1.15
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer (2003) 1.14
Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparison. Patient Educ Couns (2004) 1.14
Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol (1998) 1.13
Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer (1992) 1.13
Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer (2008) 1.13
Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem (1990) 1.12
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer (2000) 1.12
Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol (2000) 1.12
Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene (1995) 1.12
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results. Br J Ophthalmol (1998) 1.11
Non-Hodgkin's malignant lymphomata of upper digestive and respiratory tract: natural history and results of radiotherapy. Br J Cancer Suppl (1975) 1.11
The muscle-sparing latissimus dorsi flap for breast reconstruction. Plast Reconstr Surg (2009) 1.11
Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol (2009) 1.11
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer (2013) 1.11
Conservative treatment of breast cancers by mammaplasty and irradiation: a new approach to lower quadrant tumors. Plast Reconstr Surg (1995) 1.11
Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet (1990) 1.08
Loss of alleles on chromosome 18 and on the short arm of chromosome 17 in polyploid colorectal carcinomas. Int J Cancer (1988) 1.08
Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer (1994) 1.08
T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomedicine (1974) 1.07
Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer (1990) 1.07
Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet (1998) 1.07
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer (1995) 1.07
Mammographic features of 455 invasive lobular carcinomas. Radiology (1992) 1.06
Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat (1998) 1.05
A semiparametric approach for the two-sample comparison of survival times with long-term survivors. Biometrics (2001) 1.05
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol (1998) 1.05
Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg (2003) 1.04
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer (1996) 1.04
Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog (1993) 1.03
Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop (1998) 1.03
Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer (1991) 1.03
Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer (1994) 1.03
Subdivision of classical varieties of acute leukemia. Correlation with prognosis and cure expectancy. Rev Eur Etud Clin Biol (1972) 1.01
Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat (1996) 1.01